An Incidental Finding of Mucinous Colon Cancer by 18F-Choline PET/CT Determining a Change in Clinical Management of a Patient with Recurrent Prostate Adenocarcinoma by Carmelo Tuscano, Elvio Grazioso Russi, Said Al Sayyad, Stefano Pergolizzi

“…A 66-year-old-man underwent a PET/CT scan after a biochemical relapse for a prostate cancer previously treated with a laparoscopic surgical procedure which revealed a focal uptake in the posterior wall of sigmoid colon. …”
Get full text

Tumoral Prostate Shows Different Expression Pattern of Somatostatin Receptor 2 (SSTR2) and Phosphotyrosine Phosphatase SHP-1 (PTPN6) According to Tumor Progression by Ariel Ernesto Cariaga-Martinez, María Angelica Lorenzati, Mario Alejandro Riera, Marisa Angelica Cubilla, Andrés De La Rossa, Ernesto Martín Giorgio, María Mercedes Tiscornia, Esteban Mariano Gimenez, María Eugenia Rojas, Bárbara Julieta Chaneton, Dora Isabel Rodríguez, Pedro Darío Zapata

“…Prostate proliferation is dependent of androgens and many peptide hormones. …”
Get full text

18F−Prostate−Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN−2): a phase I/II study by Jisce R. Puik, Thomas T. Poels, Gerrit K. J. Hooijer, Matthijs C. F. Cysouw, Joanne Verheij, Johanna W. Wilmink, Elisa Giovannetti, Geert Kazemier, Arantza Farina Sarasqueta, Daniela E. Oprea-Lager, Rutger-Jan Swijnenburg

“…Abstract Background Current diagnostic imaging modalities have limited ability to differentiate between malignant and benign pancreaticobiliary disease, and lack accuracy in detecting lymph node metastases. 18F-Prostate-Specific Membrane Antigen (PSMA) PET/CT is an imaging modality used for staging of prostate cancer, but has incidentally also identified PSMA-avid pancreatic lesions, histologically characterized as pancreatic ductal adenocarcinoma (PDAC). …”
Get full text

Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only by Stefan Latz, Christian Fisang, Wolfram Ebert, Stefan Orth, Dirk G. Engehausen, Stefan C. Müller, Ralf Anding

“…After diagnosis of well to moderately differentiated prostate cancer by transrectal biopsy, the patient underwent an open radical prostatectomy. …”
Get full text

A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer by Xiannan Meng, Qingxuan Wu, Chengsong Cao, Wendong Yang, Sufang Chu, Hongjun Guo, Suhua Qi, Jin Bai

Subjects: “…Castration-resistant prostate cancer (CRPC)…”
Get full text

Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study by Christian Torp-Pedersen, Mette Nørgaard, Helle D Zacho, Lars J Petersen, Anna Winther Mogensen, Marie T Pank

“…Objective To determine whether preoperative staging of high-risk prostate cancer with 18F-sodium-fluoride (18F-NaF) positron emission tomography (PET) reduces the risk of skeletal metastases.Design Nationwide, population-based cohort study using real-world data.Setting The study used national health registries, including all sites in Denmark from 2011 to 2018.Participants Newly diagnosed high-risk prostate cancer patients who underwent radical prostatectomy from 2011 to 2018. …”
Get full text

Comparison of Robot-Assisted, Laparoscopic, and Open Radical Prostatectomy Outcomes: A Systematic Review and Network Meta-Analysis from KSER Update Series by Do Kyung Kim, Young Joon Moon, Doo Yong Chung, Hae Do Jung, Seung Hyun Jeon, Seok Ho Kang, Sunghyun Paick, Joo Yong Lee

Subjects: “…prostatic neoplasms…”
Get full text

Personalized metronomic radiopharmaceutical therapy through injection profile optimization via physiologically based pharmacokinetic (PBPK) modeling by Aryan Golzaryan, M. Soltani, Farshad Moradi Kashkooli, Babak Saboury, Arman Rahmim

Subjects: Get full text

PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny by Mohammad A. Alzubi, Theresa Barberi, Alan D. Friedman

Subjects: Get full text

Short-term effects of follicle-stimulating hormone on immune function, lipid, and vitamin metabolism in transiently castrated men by Jéssica Guedes, Indira Pla, Aniel Sanchez, Gyorgy Marko-Varga, Gilberto Barbosa Domont, K Barbara Sahlin, Berk Hazir, Aleksander Giwercman, Fábio César Sousa Nogueira, Johan Malm, Yvonne Lundberg Giwercman

Subjects: Get full text

PSA is not suitable as a reliable marker for seminal fluid in rectal samples collected post-mortem by Corine Müller, Elie Pascolo Tièche, Martin Zieger

Subjects: Get full text

The Impact of Atorvastatin on Intraprostatic Biomarkers – Prognostic Value of 3LS-score – Follow-up of ESTO1-Trial by Eemil Lehtonen, Maiju Vertanen, Heimo Syvälä, Teemu Tolonen, Seppo Auriola, Teuvo Tammela, Aino Siltari, Teemu Murtola

Subjects: “…Prostate cancer…”
Get full text

Development of Novel Nomograms to Predict 5- and 7-Year Biochemical-Recurrence-Free Survival in High-Risk Prostate Cancer Patients After Carbon-Ion Radiotherapy and Androgen Deprivation Therapy by Takanobu Utsumi, Hiroyoshi Suzuki, Masaru Wakatsuki, Kana Kobayashi, Atsushi Okato, Mio Nakajima, Shuri Aoki, Taisuke Sumiya, Tomohiko Ichikawa, Koichiro Akakura, Hiroshi Tsuji, Shigeru Yamada, Hitoshi Ishikawa

Subjects: “…prostate cancer…”
Get full text

Dose-volume parameter evaluation of a sub-fractionation workflow for adaptive radiotherapy of prostate cancer patients on a 1.5 T magnetic resonance imaging radiotherapy system by Georgios Tsekas, Cornel Zachiu, Gijsbert H. Bol, Jochem R.N. van der Voort van Zyp, Sandrine M.G. van de Pol, Johannes C.J. de Boer, Bas W. Raaymakers

Subjects: “…Prostate cancer…”
Get full text

The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells by Adrienne Bolden, Lynikka Bernard, Danielle Jones, Tunde Akinyeke, LaMonica V. Stewart

“…Thiazolidinediones (TZDs) dramatically reduce the growth of human prostate cancer cells in vitro and in vivo. To determine whether the antitumor effects of TZDs were due in part to changes in the MEK/Erk signaling pathway, we examined the regulation of Erk phosphorylation by the TZD troglitazone within the PC-3 and C4-2 human prostate cancer cell lines. …”
Get full text

Glutathione-S-Transferase p1 Gene Promoter Methylation in Cell-Free DNA as a Diagnostic and Prognostic Tool for Prostate Cancer: A Systematic Review and Meta-Analysis by Jinghe Ye, Mao Wu, Long He, Peng Chen, Hongtao Liu, Hongwei Yang

“…It may be helpful for the early detection of prostate cancer, but it still must be combined with traditional prostate-specific antigen (PSA) or other methylated genes to accomplish this goal.…”
Get full text

Exercise medicine as adjunct therapy during RADIation for CAncer of the prostaTE to improve treatment efficacy – protocol for the ERADICATE study: a phase II randomised controlled trial by Oliver Schumacher, Robert U. Newton, Colin Tang, Raphael Chee, Sjoerd B. Vos, Ronny S. Low, David Joseph, Dennis R. Taaffe, Daniel A. Galvão

Subjects: “…Prostate cancer…”
Get full text

Association of Androgen-Receptor Gene Mutations with the Copy Number of Androgen-Receptor Silk Protein A Complex and Glutathione-S-Transferases T1 and M1 in Prostate Cancer Patients by Yan Zhang, Xiangdi Meng, Zhaosen Ma, Zhou Sun, Zhixin Wang

“…A combination of four factors can be used to identify prostate cancer susceptibility and disease progression.…”
Get full text

Effects of postoperative physical exercise rehabilitation on cardiorespiratory fitness, functional capacity and quality of life in patients with colorectal, breast, and prostate cancer – a systematic review and meta-analysis by Mailin Beyer, Christian Bischoff, Johannes Lässing, Ines Gockel, Roberto Falz

“…However, there is a lack of high-quality trials with a higher number of participants examining the effects of postoperative exercise in patients with colorectal, breast, and prostate cancer. There is an obvious need for long-term, cancer-specific exercise therapies and their evaluation in cancer care.…”
Get full text

De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review by Hanxu Guo, Chengqi Jin, Li Ding, Jun Xie, Jing Xu, Ruiliang Wang, Hong Wang, Changcheng Guo, Jiansheng Zhang, Bo Peng, Xudong Yao, Jing Yuan, Bin Yang, Sihan Zhou

Get full text